01 January 1998
Changes in serum PICP concentrations during therapy with growth hormone in children with chronic renal failure
Maria Sieniawska, Małgorzata Pańczyk-Tomaszewska, Beata Leszczyńska, Maria Roszkowska-BlaimMed Sci Monit 1998; 4(6): CR960-965 :: ID: 451732
Abstract
The aim of the study was to evaluate serum PICP level (carboxyterminal propeptide of type I procollagen) during the treatment with recombinant human growth hormone (rhGH) of short-stature children with chronic renal failure (CRF). The work was also an attempt to establish whether PICP level during the first months of therapy had a predictive value concerning faster growth in this group of children. The study included 36 children. Group I consisted of 17 subjects aged 10.3±2.6 years treated with continuous ambulatory peritoneal dialysis (CAPD), group II was made up of 9 children on haemodialysis (HD), aged 12.5±2.1 years, while group III was formed of 10 children with pre-end-stage renal failure (PESRF), aged 10±3.3 years. All the patients received 1.1 u/kg/week subcutaneous rhGH every evening for 12 months. Serum PICP level was determined before starting rhGH treatment as well as in 1, 3, 6, 9 and 12 month of therapy. Patients' growth was measured with stadiometer every 3 months.
Results: Mean growth (DH) after 12 months of treatment was: 7.98±2.04 cm in group I, 7.37±1.9 cm in group II, 8.25±2.47 cm in group III. The highest mean PICP level was observed in 6th month of treatment (423.7±148.7 µg/l), p=0.001 in relation to mean PICP value before the beginning of therapy. There was a stronger positive correlation between PICP concentration in 1st month (r=0.5, p < 0.01) than between PICP level in 3rd and 6th month of treatment and DH after 1 year of rhGH therapy. However, we found low PICP levels in 1st month of therapy in children with satisfactory DH, i.e. over 7cm/year as well as in those with insufficient DH, i. e. below 6 cm/year.
Conclusions: 1. Mean PICP level increases during the first 6 months of treatment with rhGH. 2. PICP concentration in the first month of therapy correlates with growth acceleration in the first year of rhGH administration, but it is of no prognostic value for individual patients.
Keywords: PICP, chronic renal failure, Growth Hormone
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
21 Mar 2024 : Meta-Analysis
Economic Evaluation of COVID-19 Screening Tests and Surveillance Strategies in Low-Income, Middle-Income, a...Med Sci Monit In Press; DOI: 10.12659/MSM.943863
10 Apr 2024 : Clinical Research
Predicting Acute Cardiovascular Complications in COVID-19: Insights from a Specialized Cardiac Referral Dep...Med Sci Monit In Press; DOI: 10.12659/MSM.942612
06 Mar 2024 : Clinical Research
Enhanced Surgical Outcomes of Popliteal Cyst Excision: A Retrospective Study Comparing Arthroscopic Debride...Med Sci Monit In Press; DOI: 10.12659/MSM.941102
06 Mar 2024 : Clinical Research
Prevalence and Variation of Medical Comorbidities in Oral Surgery Patients: A Retrospective Study at Jazan ...Med Sci Monit In Press; DOI: 10.12659/MSM.943884
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952